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Abstract 
KCTD9 belongs to the human potassium channel tetramerization domain (KCTD) 
family and is of unknown biological function. Our studies in yeast showed that the yeast 
homologue of KCTD, Whi2, is required to reduce TOR (target of rapamycin) kinase 
activity, thereby slowing down cell growth and inducing autophagy. Therefore, it was 
thought that KCTD9 may be associated to autophagosomes and playing a role in inducing 
autophagy.  
 For the first time, we were able to confirm that KCTD9’s subcellular localization. 
KCTD9 forms cytoplasmic puncta that fall within the range of the size of autophagosomes. 
In order to identify these structures, KCTD9 was co-expressed with numerous cellular 
markers including endosomal and autophagy proteins. KCTD9 puncta did not co-localize 
with endosomal markers, but co-localized with LC3, a canonical marker of 
autophagosomes. Furthermore, KCTD9 co-localized with autophagy proteins involved in 
the nucleation and elongation of the autophagosome - Vps34, Beclin-1, Atg5, and Atg12. 
While KCTD9 puncta re-localize to LC3 marked structures under starvation conditions, it 
induces the formation of Vps34 and Atg5 puncta in complete media. Furthermore, KCTD9 
associated with the endoplasmic reticulum (ER) suggesting it could be localizing to 
subdomains of the ER from which autophagosomes derive from.  
Knockdown of KCTD9 leads to a decrease in the conversion of LC3-I to LC3-II 
indicating a stall in the autophagy pathway. KCTD9 could be playing a role in the 
initiation of this pathway by recruiting early autophagy proteins on the ER. Moreover, 
since it co-localized with E3-ligase Cullin-3 and acts a substrate adaptor, KCTD9 could be 
recruiting selective autophagic cargo.  
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 These results suggest that KCTD9 is a novel autophagosome-associated protein 
playing a potential role in the induction of the autophagic pathway.        
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Introduction   
 
The human KCTD protein family is a group of proteins associated with numerous 
diseases of significant public health importance including cancer, neurodegeneration, and 
obesity (Liu et al., 2013). KCTD9 has been associated with breast cancer, metastasized 
prostate tumors, and autism (Naylor et al., 2005; Paris et al., 2006; Baron et al., 2006). 
More recently, KCTD9 has been found to promote liver inflammation in patients with 
chronic Hepatitis B Virus (HBV) (Chen et al., 2013). HBV is a major worldwide health 
concern because there are about 400 million individuals infected with the virus and 1 
million deaths each year due to HBV (Grimm et al., 2013). HBV gets transmitted through 
exposure of infectious body fluids or blood and the virus replicates in the liver, but can 
eventually spread into the bloodstream (Yun-Fan Liaw et al., 2009). While acute illness 
includes liver inflammation, chronic infection can lead to liver cancer and cirrhosis (Yun-
Fan Liaw et al., 2009). Immune-mediated liver damage plays a key role in chronic HBV 
infections and KCTD9 is thought to promote hepatic injury due to its possible role in NK 
cell activation (Grimm et al., 2013; Chen et al., 2013). Therefore, better understanding 
the biological function of KCTD9 will allow to clarify its potential as therapeutic target 
for patients with chronic HBV infections (Chen et al., 2013).            
Our interest in the mammalian KCTD protein family stems from our lab’s work 
done in yeast, where a poorly characterized general stress-response gene, yeast WHI2 
(whiskey-2, “wee-2”), is the top hit in our lab’s genome-wide screen for regulators of 
nutrient-sensing and cell survival (Teng et al., 2013). Results show that WHI2-deficient 
(Dwhi2) yeast grow better on low amino acid media in comparison to wild type strains, 
but when exposed to stressful conditions, the yeast mutant has a tendency to undergo cell 
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death (Cheng et al., 2008; Teng et al., 2013). Furthermore, WHI2 is required to reduce 
TOR (target of rapamycin) kinase activity specifically following amino acid withdrawal 
(Cheng et al., 2008; Teng et al., unpublished), thereby slowing down cell growth and 
inducing autophagy, a catabolic process involving the degradation of cell components 
through the lysosomal machinery (Klionsky et al., 2005). These findings are consistent 
with the possibility that the yeast Whi2 protein may be a new upstream negative regulator 
of TOR (Teng et al., unpublished). Alternatively, instead of being an upstream regulator, 
Whi2 could directly activate autophagy that feedback inhibits TOR in yeast (Mendl et al., 
2011). Although the yeast Whi2 protein is reported to be fungi-specific, bioinformatics 
tools (HMM Pred search) identified the KCTD homologues in human genome(Teng et 
al., 2013).   
So far very few studies on KCTD/Whi2 proteins have been undertaken to 
examine their specific functions. The KCTD/Whi2 proteins contain a BTB domain and 
therefore have been proposed to act as adaptors for the E3 ubiquitin ligase Cullin-3 
(Pintard et al., 2005). BTB-domains are found in many proteins of diverse functions, but 
the best characterized BTB proteins are those in the cullin-RING ubiquitin ligases  
(CRLs) composed of a cullin, a RING protein (E3 activity) and a BTB/POZ adaptor such 
as Skp1 (Geyer et al., 2003). This E3 ubiquitin ligase complex plays an important role in 
polyubiquitination and degradation of certain protein substrates (Choo et al., 2012). 
Cullin-3 protein can bind an E3 ligase protein at its C-terminus and a BTB-containing 
protein at its N-terminus (Stogios et al., 2005). In turn, the BTB protein is thought to 
recognize specific targets for ubiquitination/neddylation (Pintard et al., 2003). Recently, 
Cullin-3 was reported to play a role in regulating the late steps of the endo-lysosomal 
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trafficking and to be important for a late step in influenza virus uncoating (Huotari et al., 
2012). Interestingly, mammalian and yeast TOR localize to lysosomal/vacuolar 
membranes (Gong et al., 2011), and vesicle trafficking pathways are known to be 
required for nutrient responses that regulate TOR in yeast, though the details remain 
unresolved (Dechant et al., 2008). Based on these findings, combined with our lab’s yeast 
Whi2 studies, my project was to investigate the potential role of human KCTD9 in 
responding to nutrients and the autophagy pathway. Our hypothesis is to determine where 
along the autophagy pathway KCTD9 participates, to examine its subcellular localization 
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The KCTD Family 
The human potassium channel tetramerization domain (KCTD) protein family 
consists of 26 members, mostly with unknown biological functions (Liu et al., 2013). 
KCTD proteins are cytoplasmic proteins that seem not binding to K+ or functiuning as 
potassium channels, but received this name since their N-terminal BTB/POZ domain 
shares the greatest sequence homology with the BTB-like tetramerization domain (T1 
domain) of voltage-dependent potassium channels (Liu et al., 2013; Dementieva et al., 
2009). While the KCTD family members have a conserved Bric-a-brack, Tram-track, 
Broad complex (BTB) domain, their C-termini can be quite variable in sequence and 
length. The BTB domain was first identified in Drosophila melanogaster and has protein-
protein interaction motif for homodimerization or heterodimerization (Dementieva et al., 
2009). There are about 400 BTB domain-containing proteins in the human genome and 9 
in yeast (Perez-Torrado et al. 2006), in which the BTB is usually located at the N-
terminus that may contain additional domains, such as zinc-finger domains, as kelch 
repeats, and FYVE (Fab1, YOTB, Vac1, and EEA1) domains (Stogios et al., 2005). The 
BTB domain allows for the KCTD proteins to self-assemble and to bind to other proteins 
(Dementieva, 2009). For example, the X-ray crystal structure of KCTD5 shows that it can 
assemble into five subunits through its BTB domain (Dementieva, 2009). As more 
research is conducted on this BTB domain-containing family, results show the 
involvement of KCTDs in cytoskeleton regulation, transcriptional repression, interaction 
with E3-ligase complex Cullin-3, and human disease (Liu et al., 2013). 
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Cullin-3 Adaptors   
Due to their BTB domains, KCTD proteins could possibly act as substrate 
adaptors for the Cullin-3 ubiquitin ligase and aid in the ubiquitination of substrate 
proteins (Furukava et al., 2005). There are eight cullin proteins that act as molecular 
scaffolds in the assembly of a multi-subunit Cullin-RING E3 ubiquitin ligase (CRL) to 
ubiquitinate cellular proteins (Sarikas et al., 2011). There are three enzymatic steps 
involved in ubiquitinating a protein - the activation occurs by the ubiquitin-activating 
enzyme E1, which allows for the transfer of the activated ubiquitin to the ubiquitin-
conjugating enzyme E2 (Bosu et al., 2008). Then the ubiquitin ligase E3, which binds the 
substrate, can bring the substrate and E2 close enough for the E2 to conjugate the 
ubiquitin onto the substrate (Bosu et al., 2008).  
The cullin protein helps to connect the substrate, through the adaptor protein, and 
the RING finger portion of the CRL, allowing for facilitation of the transfer of ubiquitin 
to the substrate by the RING-bound E2 enzyme (Hochstrasse et al., 1996). The cullin 
proteins play a crucial role in this ubiquitination process therefore regulating numerous 
cellular processes including signal transduction, transcriptional control, cell growth, and 
tumor suppression (Sarikas et al., 2011).     
Cullin-3 has been reported to control many biological functions in mammalian 
cells such as, cell death, protein trafficking, transcriptional activation, and stress 
responses (Genschik et al., 2013). In addition, cullin-3 has been associated with human 
metabolic disease, dystrophies, pseudohypoaldosteronism and cancer (Genschik et al., 
2013). The role of cullin-3 in protein trafficking is of key interest to our research as we 
consider the possible involvement of KCTD proteins in the autophagy pathway. Recent 
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studies by Huotari et al. (2012) show that cullin-3 is involved in the late steps of the 
endosomal pathway by regulating the transport of late endosomes to the lysosome. To 
study the function of cullin-3 in endosomal trafficking, influenza A virus (IAV) and 
epidermal growth factor receptor (EGFR) are tracked from their internalization from the 
cell surface (Huotari et al., 2012 When cells are depleted of cullin-3 using siRNA, both 
IAV and the EGFR are able to be internalized into late endosome/lysosome 
compartments marked by Lamp1 (Huotari et al., 2012). However, the degradation of 
EGFR and uncoating of the virus is delayed and cells begin to accumulate abnormal 
looking late endosomes and became highly vacuolized with Rab7-marked endosomes 
(Huotari et al., 2012). These results suggest that cullin-3 is involved in endosome 
maturation and it is thought that ubiquitination is involved in the process (Huotari et al., 
2012).                
            A handful of KCTD proteins have been identified as candidate substrate adaptors 
for cullin-3 including KCTD11, KCTD21, KCDT6, KCTD5, and KCTD7 (Liu et al., 
2013). The Hedgehog signaling pathway is known to be deregulated in tumors including 
medulloblastoma (Di Marcotullio et al., 2004). Gli1 and Gli2 are proteins involved in the 
Hedgehog signaling pathway and their genes are deacetylated by HDAC (histone 
deacetylase) to upregulate the Hedgehog pathway (Canettieri et al., 2010). KCTD11 was 
reported to act as an adaptor for HDAC1 to be degraded by the cullin-3 ubiquitin 
complex leading to suppression of the Hedgehog activity (Canettieri et al., 2010).  
KCTD11 has been associated with medulloblastoma when it undergoes allelic deletion or 
is expressed at low level (Di Marcotullio et al., 2004). KCTD 21 and KCTD6 have also 
been found to act as substrate adaptors for the histone deacetylase protein 1 in the 
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Hedgehog signaling pathway (De Smaele et al., 2010). While KCTD5 has also been 
shown to bind cullin-3, the nature of the substrates recognized by KCTD5 for possible 
targeting for ubiquitination is not known (Bayon et al., 2008). Similarly, KCTD7 can be 
co-immunoprecipitated with cullin-3, but no target substrate has been identified (Azizieh 
et al., 2011). It is suggested that KCTD7 may increase the conductance of voltage-gated 
potassium channels, possibly by degrading through cullin-3 ubiquitination by the 
proteasome (Azizieh et al., 2011), but this mechanism remains unproven. Further 
research is needed to verify if KCTD family proteins function dependently to cullin 
ligases, and investigate which substrates are targeted by the KCTD proteins, which would 
give more insight into the functions of the KCTD family (Liu et al., 2013).   
 
Role in Disease  
The KCTD family members have been associated with several diseases such as 
medulloblastoma, breast carcinoma, neurological diseases, obesity, and pulmonary 
inflammation (Liu et al., 2013). This section will specifically discuss the role of 
KCTD11, KCTD7, and KCTD13 in human diseases. KCTD11, located on chromosome 
17p13.2 has been identified as a tumor suppressor and this portion of the chromosome is 
commonly deleted in human medulloblastoma, a malignant pediatric brain tumor (Smaele 
et al., 2004). These tumors are thought to arise from neuronal progenitor cells during the 
development of the cerebellum (Wechsler-Reya et al., 2001). The Hedgehog signaling 
pathway, which is responsible for regulating the differentiation of the progenitor cells 
during development of the cerebellum, is not turned off in medulloblastoma, leading to 
uncontrolled growth of the progenitor cells leading to malignancy (Argenti et al., 2005). 
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As a cullin-3 substrate adaptor, KCTD11 is suggested to inhibit the Hedgehog pathway 
by preventing the nuclear localization of the Gli proteins to prevent activation of 
Hedgehog target genes (Canettieri et al., 2010). In vitro experiments showed that 
overexpression of KCTD11 can inhibit medulloblastoma formation in cell lines and 
colony formation in soft agar (Di Marcotullio et al., 2004). Furthermore, KCTD11 can 
prevent xenograft tumor growth in vivo (Di Marcotullio et al., 2004). Therefore, 
KCTD11 is considered to be a tumor suppressor due to its ability to inhibit the Hedgehog 
signaling pathway and prevent its deregulation that leads to medulloblastoma (Di 
Marcotullio et al., 2004).  
KCTD7 mutations define a subset of patients with progressive myoclonus 
epilepsy (EPM), EPM3, first identified by Bogaert et al. (2007) in a Moroccan family 
with this autosomal recessive disorder.  Patients with EPM3 usually present with seizures 
between the age of 16 to 24 months and overtime experience neurological weakening 
leading to an early death (Krabichler et al., 2012). Bogaert and colleagues, found that the 
Moroccan family members had a mutation in exon 2 of KCTD7 leading to a change from 
an arginine codon to a stop codon (R99X) revealing that KCTD7 is the potential genetic 
cause of EPM3 (Bogaert et al., 2007). Since this study, KCTD7 mutations have been 
identified in 24 patients, each with homozygous or compound heterozygous mutations 
including missense mutations R94W (Krabichler et al., 2012), R94T, D115Y, N2731, 
W289X (Kousi et al., 2012) and L108M (Lemke et al., 2012). Related disorders reported 
to be associated with KCTD7 mutations include acute onset of myoclonus, ataxia, and 
neuronal ceroidlipfuscinosis (Blumkin et al., 2012; Staropoli et al., 2012). While the 
exact function of KCTD7 is still unknown, expression of KCTD7 decreases the 
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excitability of murine cortical neurons, but also kills cells (Azizieh et al., 2011). 
Overexpressed GFP-KCTD7 punctae localize in the cytoplasm and to the plasma 
membrane. However, when the mutant form of KCTD7 (ΔR184C) was overexpressed, in 
neurons KCTD7 formed cytoplasmic aggregates, but did not localize to the plasma 
membrane (Staropoli et al., 2012). This mutant form of KCTD7 disrupts the ubiquitin-
proteasome system (UPS) leading to the accumulation of protein aggregates (Staropoli et 
al., 2012). These data are consistent with the possibility that KCTD7 may play a role in 
protein trafficking and when its mutated form contributes to changes in plasma 
membrane composition and accumulation of cytosolic proteins leading to neuronal 
dysfunction and death (Staropoli et al., 2012).                          
Genetic disorders have been linked to copy number variants (CNV) and the region 
of the 16p11.2 chromosome has been found to make individuals more susceptible to 
neurological defects when deleted or duplicated (Stankiewicz et al., 2010). This region of 
chromosome 16 has 29 genes, including KCTD13, and duplication or deletion of this 
region has been associated with schizophrenia, epilepsy, autism spectrum disorder (ASD) 
(Weiss et al., 2008). When human KCTD13 was overexpressed in zebrafish embryos it 
resulted in a microcephaly phenotype, which is associated with 16p11.2 duplication 
events (Golzio et al., 2012). Microcephaly occurs when there is less proliferation of 
neuronal progenitor cells, but an increase in apoptosis while the brain is developing 
leading to smaller head size (Golzio et al., 2012). On the other hand, suppressing the 
expression of KCTD13 in the zebrafish embryos caused macrocephaly, large head size, 
due to an increase in progenitor proliferation and no change in apoptosis, which is 
associated with 16p11.2 deletion events (Golzio et al., 2012). These results indicated that 
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KCTD13 plays a major role in head size phenotypes, which are associated with 16p11.2 
CNV, by regulating the initial steps of neurogenesis (Golzio et al., 2012). In humans, 
KCTD13 is associated with autism, some cases of schizophrenia and childhood obesity 
(McCarthy et al., 2009; Walters et al., 2010). Researchers found a family with ASD and 
other neurological disorders that had a 118-kb deletion in 16p11.2, which included the 
MVP, CDIPT1, SEZ6L2, ASPHD1 and KCTD13 genes Crepel et al., 2010). This 
deletion can actually be inherited from an asymptomatic parent or occur spontaneously. 
involving multiple loci including KCTD13 (Golzio et al., 2012). It is possible that as the 
polymerase delta-interacting protein 1 (PDIP1), KCTD13 has the ability to interact with 
proliferating cell nuclear antigen and through this interaction has the ability to regulate 
the cell cycle during neurogenesis (He et al., 2001). More research will allow for better 
understanding of why deregulation of KCTD13 leads to neurological abnormalities 
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KCTD9 
KCTD9 is considered to be a medium-sized KCTD family member made up of 
389 amino acids, and like other KCTD proteins it has a BTB near the N-terminus (amino 
acids 91-181) (Skoblov et al., 2013). Additionally, KCTD9 has a KHA domain in its N-
terminus (amino acids 1-64) and four sets of eight overlapping pentapeptide repeats 
(amino acids 118-377) (UniProt, 2014; Skoblov et al., 2013). The KHA domain is 
normally found in plant potassium channels and is needed for potassium channel 
interaction (Zimmermann et al., 2001). While both prokaryotes and eukaryotes have 
pentapeptide repeats, eukaryotes usually only contain one gene encoding pentapeptide 
repeats typically containing eight copies of the sequence similar to A(D/N)LXX (Skoblov 
et al., 2013). The most well studied pentapeptide repeat proteins are mycobacterial MfpA 
and enterococcal homologs of Qnr (Hedge et al., 2011; Merens et al., 2009). Three-
dimensional structures of these pentapeptide repeats reveal that they mimic the size, 
charge, and shape of DNA, allowing the bacteria to be resistant to quinolones, an 
antibacterial drug, but binding up DNA-binding proteins (Merens et al., 2009). In 
addition, bacterial pentapeptide repeat proteins have the ability to interact with DNA 
gyrase, an enzyme that relieves strain when DNA is being unwound by a helicase, and 
prevent it from relieving DNA strain (Hedge et al., 2011; Merens et al., 2009). It has been 
suggested that the pentapeptide repeats in KCTD9 also can act as a DNA mimic (Skoblov 
et al., 2013). KCTD9 has been reported to interact with MED20, which is part of the 
mediator complex that acts as a scaffold for assembly of the RNA polymerase II 
transcriptional complex (Merens et al., 2009).  Furthermore, genomic profiling studies 
have reported reduced or no expression of KCTD9 mRNA in breast and metastasized 
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prostate tumors (Naylor et al., 2005; Paris et al., 2006). Microarray studies have found 
declining KCTD9 mRNA expression during the progression of childhood autism (Baron 
et al., 2006). However, the actual molecular function of KCTD9, or any other KCTD 
family member, is still unknown.  
Recently, Chen et al. (2013) studied the expression of KCTD9 in blood and liver 
samples from patients with either mild chronic hepatitis B (CHB) or HBV-induced acute-
on-chronic liver failure (HBV-ACLF). HBV-ACLF was seen in numerous patients with 
chronic hepatitis B infection who have developed liver failure due to hepatic necrosis 
(Chen et al., 2013). It is thought that immune-mediated mechanisms are involved in the 
necrosis process especially cytotoxic T cells and natural killer (NK) cells (Chen et al., 
2013). Peripheral blood mononuclear cells (PBMCs) were examined and KCTD9 is 
found to be mainly localized in the cytoplasm in mild CHB patients, but has both 
cytoplasmic and nuclear localization in HBV-ACLF patients (Chen et al., 2013). It is 
thought that KCTD9 translocates to the nucleus in HBV-ACLF patients, where it is 
suggested to be a contributing factor in the severity of the disease (Chen et al., 2013). 
Interestingly, other KCTD proteins, including KCTD1, 10, and 15 have been reported to 
translocate to the nucleus and interact with transcription factors, however, this has not 
been established for KCTD9 (Ding et al., 2009; Liu et al., 2009; Zarelli et al., 2013).        
KCTD9 is highly expressed in peripheral and hepatic NK cells of HBV-ACLF 
patients in comparison to those with mild CHB and the high level of KCTD9 expression 
in patients with chronic HBV was linked to the severity of liver damage (Chen et al., 
2013). PBMC gene expression profiling showed that 263 genes from 8600 were highly 
upregulated in HBV-ACLF patients and KCTD9 was one of these genes (Chen et al., 
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2013).  Such high expression of KCTD9 may cause alterations in NK cell function and 
thereby increasing hepatic damage (Chen et al., 2013). Transfecting NK92 cells with 
KCTD9 caused a significant increase in NK cell cytotoxic activity and release of IFN-γ 
(Chen et al., 2013). However, when shRNA against KCTD9 was transfected in NK92 
cells, there was a decrease in NK cell activation and cytotoxicity of hepatic cells (Chen et 
al., 2013). These results suggest the potential role of KCTD9 in the activation of NK 
cells, but the mechanism is still unclear (Chen et al., 2013). However, KCTD9 serves as a 
potential therapeutic target for HBV-ACLF patients (Chen et al., 2013). Another study 
further consolidated the role of KCTD9 in hepatic damage in HBV-ACLF while testing 
an anti-hepatic failure compound (AHFC) using the mouse model of acute hepatic failure 
infected with MHV-3 virus (Huang et al., 2009). AHFC decreased the expression of 
KCTD9 thereby preventing hepatic damage (Huang et al., 2009). Other immune-related 
genes like KCTD9 that were decreased in their expression in response to AHFC include 
Bcl-2, IL-8, IL-6, and IFN-γ (Huang et al., 2009). 
Bioinformatic (STRING 8.2) analysis predicts that KCTD9 may interact with 
SHB (SH2 domain-containing adaptor protein B), which is involved in signal 
transduction pathways of T cell receptors, IL-2, and apoptosis signaling (Lindholm et al., 
2002). It is plausible that KCTD9 acts as a substrate adaptor protein, especially since it 
has been reported that the KCTD proteins could be substrate adaptors for the E3-ligase 
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Autophagy  
 Autophagy is a regulated cellular process that involves the bulk degradation of 
cytoplasmic components including long-lived proteins and whole organelles (Mizushima, 
2007). This process is highly conserved from yeast to mammals and is different from the 
endocytic pathway, which involves the lysosomal degradation of extracellular and plasma 
membrane proteins (Mizushima, 2007). There are three types of autophagy, which 
include macroautophagy, microautophagy, and chaperone-mediated autophagy 
(Ravikumar et al., 2010). Microautophagy and chaperone-mediated autophagy both 
directly take cytoplasmic components to the lysosome, but macroautophagy (hereafter 
referred to as autophagy) involves the formation a double-membraned structure called the 
autophagosome (Ravikumar et al., 2010). While autophagy occurs in the cell at a basal 
level, it can be upregulated in response to stress situations such as starvation, pathogens, 
and endoplasmic reticulum (ER) stress (Ravikumar et al., 2010). The formation of the 
autophagosome allows for the elimination of cytoplasmic materials including harmful 
protein aggregates and microbes and recycling of nutrients (Ravikumar et al., 2010).    
 While the membrane source for the formation of autophagosomes is still debated, 
the ER is generally agreed to be one of the membrane sources (Geng et al., 2010). 
Autophagy is disrupted in yeast strains that are defective in the early stages of the 
secretory pathway involving ER-to-Golgi transport, indicating a role for the ER as a 
membrane source (Geng et al., 2010). Pre-autophagosome membrane projections that 
grow from the ER are surrounded by rough ER (Codogno et al., 2012). When cells have a 
block in the maturation of pre-autophagosomal structures there is an accumulation of ER-
associated early autophagic structures (Codogno et al., 2012). Aside from the ER, 
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mitochondria have also been suggested to be another membrane source (Codogno et al., 
2012). Research in mammalian cells has shown that the outer mitochondrial membrane 
can be contiguous with autophagosomes, and fluorescently labeled mitochondrial lipids 
appear to be transferred to the autophagosome (Codogno et al., 2012). In addition, 
recently it has been found that there are connections between the ER and mitochondria 
for the transfer of proteins between the two structures (Tooze et al., 2010). These newly 
characterized ER-mitochondrial connections could also act as a source of membrane for 
autophagosomes (Tooze et al., 2010). Other possible sources of membrane include the 
plasma membrane, the Golgi complex and endocytic vesicles (Codogno et al., 2012; 
Geng et al., 2010).  
 
The Autophagy Pathway   
The mTOR (mammalian/metabolic target of rapamycin) pathway is a key 
regulator of mammalian autophagy (Ravikumar et al., 2010). The mTOR signaling 
molecule is a Ser/Thr kinase that actively suppresses autophagy in rich nutrients, and 
stimulates the initiation of mRNA translation, ribosome biogenesis, transcription, and 
cytoskeletal reorganization (Ravikumar et al., 2010). The mTOR protein is found in two 
main complexes – mTORC1, which responds to nutrient status and negatively regulates 
autophagy, and mTORC2, which is less well characterized but a role in autophagy is not 
clear (Ravikumar et al., 2010). mTORC1 inhibits autophagy in the presence growth 
factors, energy, and amino acids, but when there is a lack of amino acids, growth factors, 
or an increase in the AMP/ATP ratio, mTORC1 is inhibited, allowing for the initiation of 
autophagy (He et al., 2009). In nutrient rich conditions mTORC1 phosphorylates Unc-51-
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like kinase 1 (ULK1) and 2 (ULK2), and autophagy-related protein 13 (Atg13) thereby 
inhibiting autophagy induction (He et al., 2009). During starvation conditions, mTORC1 
is inhibited and ULK1 and ULK2 undergo autophosphorylation and phosphorylate Atg13 
and focal adhesion kinase family-interacting protein of 200 kD (FIP200) (He et al., 
2009). This phosphorylation step is thought to be crucial to cause the translocation of 
ULK1/2, Atg13, and FIP200 complex to pre-autophagosomal structures (Alers et al., 
2012). The ULK1/2, Atg13, and FIP200 complex is the most upstream of the autophagy 
pathway known and is crucial for the recruitment of the next autophagy-related protein 
complexes (Alers et al., 2012).   
After the induction of autophagy, nucleation and formation of the phagophore 
membrane, a double-membrane structure that eventually develops into an 
autophagosome, is mediated by the class III phosphatidylinositol 3-kinase (PtdIns3K) 
complex, which includes the vacuolar protein sorting 34 protein (Vps34/PI3K), p150, 
Atg14, and Beclin 1 (He et al., 2009; Tooze et al., 2010). Vps34 is responsible for 
producing phosphatidylinositol 3-phosphate (PI3P) within subdomains of the ER, a 
membrane source for autophagosomes, which become nucleation sites for 
autophagosome biogenesis (Devereaux, 2013). Furthermore, these PI3P sites are 
important in recruiting to the isolation membrane other autophagy proteins including 
those with FYVE domains (which bind PI3P), PX domains, and WD-repeat domains 
(Devereaux, 2013). These proteins such as, WD repeat domain phosphoinositide-
interacting (WIPI) protein, act as scaffold proteins for the recruitment of additional 
autophagy proteins required for elongation and closure of the autophagosome 
(Devereaux, 2013). Beclin 1, another PI3K complex member, is regulated by B-cell 
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lymphoma/leukemia (Bcl-2), an antiapoptotic protein (He et al., 2009). In nutrient-rich 
conditions, Bcl-2 sequesters Beclin 1, but Beclin 1 dissociates from Bcl-2 for autophagy 
induction (He et al., 2009). The Vps34/PI3K complex facilitates the recruitment of two 
ubiquitin-like conjugation systems to the phagophore – Atg12-Atg5-Atg16 and LC3 (He 
et al., 2009).  
The first ubiquitin-like conjugation system involved in the elongation and closure 
of the phagophore is the Atg12-Atg5-Atg16 complex (Geng et al., 2008). Atg7 activates 
the ubiquitin-like protein Atg12 and then Atg10, conjugates Atg12 to Atg5 (Geng et al., 
2008). The Atg12-Atg5 conjugate binds to Atg16, a coiled-coil protein, and this complex 
forms a tetramer attaching to the phagophore (Mizushima et al., 2003). The second 
ubiquitin-like system is the LC3 conjugation system, where Atg4, a cysteine protease, 
cleaves LC3 at the C-terminus to form the cytosolic LC3-I with a C-terminal glycine 
residue (Fujita et al., 2008). LC3-I gets conjugated to phosphatidylethanolamine (PE) by 
Atg7 and Atg3, creating the lipidated form LC3-II (Mizushima, 2007). LC3-II gets 
attached to both the inner and outer faces of the phagophore membrane at sites 
determined by the Atg12-Atg5-Atg16 complex (Kabeya et al., 2000). LC3 has the ability 
to control the size of the autophagosome by determining the membrane curvature (Xie et 
al., 2008). Furthermore, LC3 is considered to be the gold-standard marker for the 
detection of autophagosomes by immunofluorescence microscopy, and the conversion of 
LC3-I to LC3-II is widely used to monitor autophagy induction on immunoblots 
(Rosenfeldt, 2012).  
Once the autophagosome formation is complete, Atg4 cleaves LC3 from its PE 
moiety on the outer membrane of the autophagosome, recycling the LC3 back into the 
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cytoplasm (Kirisako et al., 2000). Other autophagy proteins, such as Atg12 and Atg5, 
also get cleaved off the autophagosome, but the mechanism of how they are recycled is 
still not clear (Kirisako et al., 2000). The final step of the process involves the fusion of 
the autophagosome to the lysosome (Jager et al., 2004). This fusion is mediated by the 
small GTPase Rab7 and LAMP-2, a lysosomal membrane protein, but the mechanism has 
not been fully characterized (Jager et al., 2004). After the autophagosome-lysosome 
fusion occurs, a number of lysosomal/vacuolar acid hydrolases degrade the contents of 
the autophagosome (Jager et al., 2004). Certain molecules, such as amino acids, get 
recycled back to the cytoplasm for protein synthesis and other cellular functions during 
starvation (He et al., 2009).          
 
Innate and Adaptive Immunity   
 While autophagy plays a role in numerous cellular functions, its role in 
inflammation and the immune response is starting to gain more attention (Kuballa et al., 
2012). In addition, since KCTD9 plays a potential role in NK cell activation (Chen et al., 
2013) and possibly the autophagy pathway, it is appropriate to highlight the role 
autophagy in the innate and adaptive immune systems. More research has begun to focus 
on the role of autophagy in immune function due to the association of autophagy genes 
and inflammatory disorders such as Crohn’s disease (Kuballa et al., 2012). It has been 
shown that autophagy plays a crucial role in intracellular pathogen sensing and defects in 
autophagy can render an individual more susceptible to infection (Shin et al., 2010). 
Furthermore, autophagy functions by bridging the innate and adaptive immune systems 
since it plays a role in thymic selection, antigen presentation, lymphocyte homeostasis 
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and survival, and cytokine production (Kuballa et al., 2012).   
In general, MHC class II antigens are produced through endocytosis of the protein 
antigens from extracellular regions and undergo lysosomal degradation before loaded 
onto the MHC class II molecule (Rammensee et al., 1997; Neefjes, 1999). More recently 
it has been shown that cytoplasmic proteins and pathogens can end up into the lysosome 
by autophagy and be presented by MHC class II molecules (Paludan et al., 2005). MHC 
class II molecules from human B cells are found to be intracellular molecules and under 
starvation conditions, which induces autophagy; more of these peptides are presented 
(Dengjel et al., 2005). In addition, the loading compartment of the MHC class II 
molecules in thymic epithelial cells and dendritic cells co-localize with autophagosomes, 
further supplementing the idea that autophagy plays a role in antigen presentation (Kasai 
et al., 2009). Furthermore, studies have shown that dendritic cells require autophagy in 
order to process and present extracellular pathogens onto MHC class II molecules (Lee et 
al., 2010). Dendritic cells are responsible for presenting pathogen antigens in order to 
prime T cells (Lee et al., 2010). However, mice with Atg5-deficient dendritic cells are 
unable to prime their CD4+ T cells after been infected with Herpes Simplex Virus (Lee et 
al., 2010). The Atg5-deficient dendritic cells are unable to properly process and present 
antigens on their MHC class II molecules, cathepsins transport to MHC class II 
processing compartments is hindered, and there is a delay in fusion between 
autophagosomes and lysosomes (Lee et al., 2010).      
Numerous autophagy factors play essential roles in B and T cell functions 
(Kuballa et al., 2012). When Atg7 is deleted in the hematopoietic cells of mice, they have 
a reduced number of B and T lymphocytes in the periphery indicating the role of Atg7 in 
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lymphocyte maintenance (Mortensen et al., 2010). Specific studies in B cells have shown 
the need for Atg5 in B cell development and maintenance of the B-1a B cell lineage 
(Miller et al., 2008). Mice with B-cell specific deletion of Atg5 have a much lower 
number of B-1a B cells in the periphery in compared to other B cell lineages (Miller et 
al., 2008). Furthermore, mice with Atg5-deficient B cell progenitors are not able to 
develop into mature B cells because they cannot transition from pro- to pre-B cells 
resulting in cell death (Miller et al., 2008). Another autophagy protein, Beclin 1, is 
known to play a role in early B cell development (Arsov et al., 2011). Beclin 1-deficient 
mice have fewer lymphoid progenitor cells including common lymphoid progenitors and 
hematopoietic stem cells in the bone marrow compared to wild-type mice (Arsov et al., 
2011). However, Beclin 1-deficient mice still have a normal level of peripheral B cells 
(Arsov et al., 2011). Therefore, while Beclin 1 and Atg5 plays an important role in B cell 
development, only Atg5 and Atg7 are invovled in the maintenance of peripheral B cells 
(Kuballa et al., 2012).        
Similarly, autophagy proteins including Beclin 1, Atg3, Atg5, and Atg7 play a 
critical role in the development, maintenance, and survival of T cells (Kuballa et al., 
2012). Mice that have Atg3-, Atg5-, or Atg7-deficient T cells have T cells with less 
thymic cellularity (Jia et al., 2011). In addition, naïve peripheral CD4+ and CD8+ T cells 
that lack Atg3, Atg5, or Atg7 have reduced peripheral numbers, undergo increased 
apoptosis, and have difficulty proliferating (Jiae et al., 2011; Hubbard et al., 2010). When 
these autophagy-deficient T cells were examined, it was found that they had 
supranumerary mitochondria and increased ROS levels (Hubbard et al., 2010; Pua et al., 
2009). When T cells mature and go to peripheral organs they clear their mitochondria, 
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unless autophagy is impaired (Pua et al., 2009). Mitophagy, a form of autophagy that 
removes damaged mitochondria plays an important role in clearing proliferating T cells’ 
mitochondria when they shift to glycolytic metabolism after being activated (Mao et al., 
2011). As more research is performed to unveil the role of autophagy in innate and 
adaptive immune pathways it is becoming clear that autophagy proteins play a crucial 
role in the immune system. Furthermore, understanding the role the KCTD family plays 
in the autophagy pathway could lead to the discovery of possible immune-related 
function the KCTD proteins.                 
 
Viruses, Cancer, and Neurodegenerative Diseases  
Defective autophagy has been implicated in an increasing number of human 
diseases, from viral infections to cancer and neurodegeneration (Levine et al., 2008). 
Autophagy plays anti-viral and pro-viral roles in the life cycle of numerous viruses 
(Kudchodkar et al., 2009). Anti-viral roles include the targeting of viral proteins by 
autophagy proteins for lysosomal degradation (Kudchodkar et al., 2009). Autophagy 
proteins also initiate innate and adaptive immune responses against viral pathogens 
(Kudchodkar et al., 2009). On the other hand, certain viruses use the autophagy pathway 
in order for intracellular growth or non-lytic cellular egress (Kudchodkar et al., 2009). 
More recently, research emphasis is given to interfere with the beneficial aspects of 
autophagy for viruses destruction (Kudchokar et al, 2009). Many viruses have developed 
ways to escape their targeted degradation by autophagy (Kudchokar et al, 2009). Herpes 
simplex virus type 1 (HSV-1) encodes a protein called ICP34.5 that can interact with the 
autophagy protein Beclin 1 in order to prevent autophagy induction (Talloczy et al., 
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2006). Certain RNA viruses including poliovirus, dengue virus-2 (DENV2), rotavirus, 
and influenza virus A prevent autophagosome-lysosome fusion (Schmid et al., 2007). The 
influenza virus A viral M2 protein inhibits autophagosome-lysosome fusion and thereby 
can prevent MHC class presentation of viral particles (Schmid et al., 2007). A handful of 
DNA viruses including adenovirus, Epstein-Barr virus (EBV), and hepatitis B virus 
(HBV) actually activate the autophagy pathway in order to increase their viral replication 
(Jiang et al., 2011). Due to KCTD9’s association with HBV understanding the 
relationship of HBV and autophagy could help provide more insight into the function of 
KCTD9.   
It is known that HBV enhances autophagy to promote the replication of its 
proteins. HBV is able to use both direct and indirect triggers in order to induce autophagy 
(Li et al., 2011). Direct mechanisms involved viral elements that trigger autophagy (Li et 
al., 2011). Indirect mechanisms involve the cell inducing autophagy due to cellular stress 
caused by the virus (Li et al., 2011). Researchers have shown that HBV expression is 
linked to autophagy induction and specifically the formation of early autophagosomes 
(Sir et al., 2010). However, even though autophagy is induced, autophagic protein 
degradation does not increase (Sir et al., 2010). However, even though autophagy is 
induced, autophagic protein degradation does not increase (Sir et al., 2010). Therefore it 
is thought that HBV acts at the early stages of autophagy and possibly delays 
autophagosome maturation (Sir et al., 2010). Further research will allow for the better 
understanding of how exactly HBV induces the early stages of autophagy and this may 
provide more insight into the possible role being played by KCTD9 in chronic HBV 
infections.            
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Due to the homeostatic functions of autophagy, disruption of the process can 
allow for the promotion of tumorigenesis (Matthew et al., 2009). Since autophagy 
removes damaged organelles and proteins and can limit cell growth and genomic 
instability, it functions as a tumor suppression mechanism (Matthew et al., 2009). Beclin 
1 heterozygous mice were tumor-prone meaning that it is a haplosufficient tumor 
suppressor gene (Qu et al., 2003). When Beclin 1 is overexpressed thereby over 
stimulating autophagy tumor development can be inhibited (Liang et al. 1999). When 
autophagy is defective, there is an accumulation of p62/SQSTM 1 protein aggregates, 
damaged mitochondria, and misfolded proteins leading to the creation of reactive oxygen 
species (ROS) (Matthew et al., 2009). This can cause DNA damage, which leads to 
genomic instability and the development of tumors (Matthew et al., 2009). On the other 
hand, cancer cells use autophagy to develop stress tolerance and survive (Semenza et al., 
2010). Cancer cells can induce autophagy in order to cope with metabolic and cytotoxic 
stressors such as hypoxia and nutrient deprivation (Semenza et al., 2010). Autophagy-
deficient cancer cells have difficulty surviving when exposed to metabolic stress in 
comparison to autophagy-proficient cells (Matthew et al., 2009). Human pancreatic 
cancer cell lines and tumor specimens have increased levels of autophagy, which allow 
for tumor growth by sustaining energy production. Inhibiting autophagy in these cells 
actually caused tumor regression and allowed for longer survival of genetic mouse 
models (Yang et al., 2011). Autophagy can be considered as a key target for cancer 
treatment due to its role in tumor suppression and in some instances tumor progression 
(Granville et al., 2007). By stimulating autophagy using rapamycin, a drug that inhibits 
mTOR, 90% reduction in lung tumors have been observed in mice (Granville et al., 2007) 
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while inhibiting autophagy in tumor cells has allowed for anticancer drugs to work more 
efficiently (Zhineng et al., 2011).          
 In neurons, it appears that autophagy plays an even more crucial role in the 
maintenance of cellular homeostasis since neurons are postmitotic and cannot get rid of 
abnormal protein accumulation through cell division (Son et al., 2012). Most 
neurodegenerative diseases are characterized by misfolded protein aggregates including 
Alzheimer’s disease, Parkinson’s disease, tauopathies, Huntington’s disease, 
spinocerebellar ataxias (Ross et al., 2004). Mice with autophagy defects in neurons start 
to develop intracellular inclusions in the brain and neurodegenerative symptoms even 
though they did not express any disease-causing aggregate-prone proteins (Congcong et 
al., 2006). Atg5−/− and Atg7−/− deficient mice are born normally, but start to develop 
aging-related neurodegeneration including tremors, limb clasping, and ataxic walking 
(Congcong et al., 2006). In addition, these mice lost their Purkinje cells and ubiquitin-
positive inclusion bodies in the cerebral cortex, cerebellum hypothalamus, which are 
signs of neurodegeneration (Congcong et al., 2006). Furthermore, these autophagy-
deficient mice die within 28 weeks (Congcong et al., 2006). Autophagy is considered to 
be a potential target to prevent the accumulation of certain protein aggregates responsible 
for neurodegeneration (Ravikumar et al., 2004). Rapamycin has been used as a potential 
therapeutic agent for clearance of aggregate proteins and reduction of neurodegenerative 
symptoms in both Drosophila melanogaster and mice (Ravikumar et al., 2004). 
However, long-term use of rapamycin has been reported to cause adverse side effects, 
such as immunosuppression, and poor wound healing (Winslow et al., 2007). Further 
insight into the role autophagy plays in neurodegeneration and other possible therapeutic 
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agents will allow the development of more adequate treatment options for patients 
suffering with neurodegenerative disease (Winslow et al., 2007).      
 Our goal is to better understand the autophagy pathway and its role in human 
diseases.  While the KCTD protein family still remains largely understudied, they have 
been shown to be associated with a number of human diseases.  Determining whether the 
KCTDs play a role in the autophagy pathway could provide more insight about the 
function of these proteins and the autophagy pathway, and KCTDs could serve as 
possible therapeutic targets. 
                                                                         
    
                              
                                                                                                                                                                             











	   26	  
Methods 
Plasmid Constructs   
Full-length human KCTD9 cDNA was PCR amplified and inserted into expression 
vectors pDB59 and pHML8 using In-Fusion cloning. Mutant constructs were created by 
developing primers in order to PCR amplify either the N-terminus region or C-terminus 
region of KCTD9 cDNA and inserted into expression vector pDB59 using In-Fusion 
cloning. All four constructs were verified by sequence analysis. RFP-Rab5 and myc-
ULK1 plasmids were purchased from Clonetch. GFP-Rab7, LAMP1-RFP, RFP-LC3, 
mCherry-Atg5, Vps34-FLAG, and FYVE-dsRed were obtained as gifts from other 
laboratories. 
 
Cell Culture and Autophagy Induction 
African Green monkey kidney cells (COS7) and mouse neuroblastoma (N2a or Neuro-2) 
cells were cultured with Dulbecco's modified Eagle's medium (DMEM; Invitrogen) 
supplemented with 10% fetal bovine serum and 1% penstrep. Cultures were incubated at 
37°C, 5% CO2. Autophagy was induced under starvation conditions by incubating 
cultures with amino acid-free and serum-free DMEM for 4 hours or by treating with 
rapamycin (50nM) for 2 hours. 
 
Transfection and Immunostaining 
Cells were plated on coverslips in a 24-well plate 24 hours before transfection. Cells were 
transfected with a total of 0.375ug of DNA, which was incubated with 0.75ul of 
Lipofectamine 2000 (Invitrogen) and 50ul of Opti-MEM medium per well. The mix was 
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directly added to 500ul of Opti-MEM in each well and incubated for 5 hours after which 
the Opti-MEM was removed and DMEM was added. After 19 hours cells were washed 
with cold PBS and were fixed using 4% paraformaldehyde for 10-15 minutes at room 
temperature. Cells were washes again with cold PBS and permeabilized with 0.2% 
Triton-X100 for 5 minutes at room temperature. Cells were blocked for 30 minutes with 
2% goat serum at 4°C and then treated with primary antibody (1:1000 dilution) for 2 
hours at room temperature. Cells were washed with cold PBS and were blocked once 
again with goat serum for 30 minutes at 4°C before treating with secondary antibody 
(1:1000 dilution) for 1 hour.  Cells were washed with cold PBS and were treated with 
DAPI (1:4000 dilution) for 10 minutes at room temperature and then mounted onto slides 
using Gold Anti-fade Reagent. Slides were left at 4°C overnight before acquiring images.         
 
Fluorescence Microscopy and Data Analysis 
A Nikon 90i fluorescence microscope was used to acquire images at 100x objective and 
analyzed using Volocity analysis software (PerkinElmer). Three independent experiments 
were quantified using the 60x objective and are presented as mean ±SD of the mean for 
300-400 cells per sample. 
 
Protein Co-immunoprecipitation   
Two DNA plasmids were transfected into COS7 cells on a 6 well plate in equal amounts. 
24 hours later, cells were lysed using cold isotonic lysis buffer (0.2% NP-40, 142.5 mM 
KCl, 5mM MgCl2, 10 mM HEPES, 1 mM EGTA at pH 7.5) with protease inhibitor 
cocktail and phosphatase inhibitor. Cell lysates were incubated at 4°C with GFP antibody 
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(Invitrogen) overnight. The next day Protein-G-agarose beads (Santa Cruz) were 
incubated for 4 hours at 4°C . Cell lysates were washed four times with cold PBS, 
suspended in 1x Sample buffer (50 mM Tris-HCl pH 6.6, 2% SDS, 10% glycerol, 1% β-
mercaptoethanol, 0.02 % bromophenol blue) and vortexed 3 times. Lysates were boiled 
for 2 minutes at 100°C before performing western blot analysis.    
 
Lysate collection and Western blot Analysis 
Mouse lysates were obtained from 5-week-old NIH Swiss mouse and suspended in RIPA 
buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris pH 
8.0). N2a or COS7 cells were transfected with DNA plasmids and cell lysates were 
collected 24 hours later and suspended in 1x Sample buffer. Once lysates were collected 
they were vortexed 5 times and boiled for 3 minutes at 100°C . Lysates were loaded onto 
12% SDS-PAGE gel, transferred onto polyvinylidene difluoride (PVDF) membranes 
(Bio-Rad Laboratories), and detected with enhanced chemiluminescence (ECL) Western 
blotting detection reagents (GE Healthcare Life Sciences).        
 
RNA interference of KCTD9 
N2a cells were seeded in 12-well plate for 19 hours before transfection. A negative 
control scramble siRNA or KCTD9 Smartpool siRNA (Dharmacon) was transfected 
using Dharmafect according to the manufacturer's protocol. After 72-96 hours of 
transfection, cell lysates were collected using 1x Sample buffer, vortexed 3 times, boiled 
for 5 minutes at 100°C and subjected to western blot analysis.      
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Results  
Expression of human KCTD9 forms cytoplasmic puncta in COS7 and N2a cells   
In order to characterize human KCTD9 two full-length constructs were made: one 
with a N-terminal HA-tag and another with a N-terminal GFP-tag (Fig. 1). These 
constructs were expressed in COS7 cells and resulted in the formation of cytoplasmic 
puncta. Both HA-KCTD9 and GFP-KCTD9 predominantly formed “vesicle-like” puncta, 
which had an average diameter of 1.25 µm (Fig. 2A (right), 2C). Autophagosomes have 
been reported to range from 0.5-1.5 µm (Mizushima et al., 2002). In addition, expression 
of constructs resulted in the formation of smaller puncta, with an average diameter of 0.7 
µm, and more elongated structures as shown for the HA-KCTD9 construct (Fig. 2A (left 
and middle). HA-KCTD9-containing structures were quantified as small puncta, 
elongated puncta, and “vesicle-like” puncta (Fig. 2B). To confirm these structures are not 
artifact, an empty GFP expressing vector was transfected into COS7 cells and resulted in 
a diffuse cytoplasmic (Fig. 2C). Therefore, expression of HA-KCTD9 and GFP-KCTD9 
in COS7 cells form cytoplasmic puncta remaining to be identified.  
 In order to confirm these structures, HA-KCTD9 was transfected into N2a cells 
resulting in the formation of similar cytoplasmic structures - round punta, elongated 
puncta, and “vesicle-like” puncta (Fig. 3A). When quantified at 19 hours post-
transfection, HA-KCTD9 mainly formed the small round puncta. However, 40 hours 
post-transfection there was an increase in the number of cells with “vesicle-like” puncta 
(Fig. 3B). Once again these structures were similar in size to autophagosome - the round 
puncta had an average diameter of 0.63 µm and the “vesicle-like” puncta were 1.46 µm. 
In comparison to 19 hours, there was more HA-KCTD9 protein expressed at 40 hours 
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(Fig. 3C). Therefore, it can be concluded that human KCTD9 localizes to the cytoplasm 
forming small puncta that can be transformed into larger “vesicle-like” 
structures.                    
 
KCTD9 self-interacts via BTB domain  
 To further characterize KCTD9, two mutant constructs were created : a N-
terminal HA-tagged BTB domain-containing construct and a N-terminal HA-tagged 
pentapeptide repeat containing construct (Fig. 1). The BTB domain containing construct 
included the first half of the protein, from amino acids 1 to 194 (hereafter referred to at 
KCTD9-194x). While the pentapeptide repeat containing construct included the C-
terminal of KCTD9 from amino acids 186 to 389 (hereafter referred to as KCTD9ΔN).  
When KCTD9-194x was transfected in COS7 (Fig. 4A left) or N2a (Fig. 4B left) cells it 
formed very small puncta. These puncta seem to be lined up in an organized fashion as 
though they are vesicles being trafficked, but live imaging will be needed to test this 
hypothesis. On the other hand, KCTD9ΔN in both COS7 (Fig. 4A right) or N2a (Fig. 4B 
right) cells form a diffuse yet string-like network in the cytoplasm. This structure is very 
reminiscent of endoplasmic reticulum, which has been reported to look like an 
interconnected network of tubules (Voeltz et al., 2002). These mutant constructs will be 
used to determine the nature of the cellular structures containing KCTD9 and to study 
BTB domain protein interaction. 
 KCTD9 contains a BTB domain, a protein-protein interaction domain that has 
been reported to allow for numerous cellular functions such as targeting proteins for 
ubiquitination, transcriptional regulations, and cytoskeleton dynamics. BTB domains can 
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allow for proteins to either self-associate or interact with non-BTB proteins (Stogios et 
al., 2005). In order to confirm that KCTD9 can self-associate through its BTB domain, a 
co-immunoprecipitation was performed where full length GFP-KCTD9 was used to 
examine if it can pull down HA-KCTD9-194x, HA-KCTD9ΔN or HA-KCTD13-141x. 
Full length GFP-KCTD9 was able to interact with its own BTB domain since it pulled 
down the KCTD9-194x mutant (Fig. 4C left). As expected, it did not pull down the 
KCTD9ΔN mutant lacking the BTB domain (Fig. 4C middle). Interestingly, full length 
GFP-KCTD9 was not able to pull down the BTB containing mutant KCTD13-141x (Fig. 
4C right). These results confirm that KCTD9 can self-associate through its BTB domain 
and furthermore this interaction is specific for its own BTB domain since it did not 
interact with KCTD13’s BTB domain. In addition, these results suggest that KCTD9 can 
make larger “vesicle-like” structures by interacting with its BTB domain.             
 
KCTD9 co-localizes with Cullin-3   
 The KCTDs have been reported to be substrate adaptors for the E3 ubiquitin 
ligase cullin-3 via their BTB domain (Furukava et al., 2005).  Cullin-3-myc was 
expressed in COS7 cells and it formed puncta that were reminiscent of HA-KCTD9-
194x, but the puncta seemed slightly smaller (Fig. 5A). When Cullin-3-myc was co-
expressed with HA-KCTD9 they co-localized in large “vesicle-like” structures (Fig. 5B). 
The HA-KCTD9 structures alone form smaller vesicles, but co-expression with Cullin-3-
myc induced the formation of larger structures. It is possible that these larger structures 
could contain proteins for which KCTD9 is a substrate adaptor. Furthermore, HA-
KCTD9-194x puncta co-localized with Cullin-3-myc since this was the BTB-containing 
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portion of KCTD9 (Fig. 5C). These results suggest that KCTD9 and Cullin-3 have the 
ability to localize to the same structures and may possibly interact. Co-
immunoprecipitation experiments will confirm potential interaction between KCTD9 and 
Cullin-3.         
 
KCTD9 does not co-localize with endosomal markers  
Huotari et al., reported the role of Cullin-3 in endosomal maturation and BTB 
domain containing-proteins possibly in endolysosomal and recycling pathways (2012). 
Therefore, HA-KCTD9 and HA-KCTD9-194x constructs were co-expressed with known 
endosomal markers in N2a cells. Rab5 localizes to early endosomes and the cytoplasmic 
side of the plasma membrane (Gorvel et al., 1999). When Rab5-RFP was co-expressed 
with HA-KCTD9 or HA-KCTD9-194x they formed distinct puncta revealing no co-
localization (Fig. 6A, 6B). Furthermore, the Rab5-RFP puncta localized to a distinct part 
of the cytoplasm away from the HA-KCTD9 puncta (Fig. 6A). In addition, HA-KCTD9 
did not co-localize with GFP-Rab7 (Fig. 6C) nor with Lamp1-RFP (Fig. 6D), which are 
markers of late endosomes and lysosomes (Jager et al., 2004). Treatment of CCCP to 
induce mitophagy or starvation to induce macroautophagy did not induce co-localization 
of KCTD9 structures with endosomal markers (data not shown). KCTD9 may then not 
play a direct role in the endocytic pathway.     
 
KCTD9 puncta localize to autophagosomes  
 Whi2, the yeast homologue of KCTD9, is thought to play a role in nutrient 
sensing and possibly in the induction of autophagy (Teng et al., unpublished).  
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Furthermore, Cullin-3 has been reported to be a LC3 interacting protein (Behrends et al., 
2010). Therefore, in order to test our hypothesis that KCTD9 is involved in autophagy, 
KCTD9 was co-expressed with autophagy markers in COS7 cells (Table 2). LC3 is 
consider to be the most widely accepted marker of autophagosomes and can form small 
puncta in the cytoplasm at basal conditions and puncta can increase when autophagy is 
induced (Levine et al., 2011; Kabeya et al., 2000). In complete media, RFP-LC3 resulted 
in the formation of about 9-13 puncta per cell in three individual experiments (Fig. 7A). 
When autophagy was induced by amino acid and serum withdrawal (starvation) for 4 
hours the number of RFP-LC3-labelled autophagosomes increased to about 17-21 puncta 
per cell in three individual experiments (Fig. 7A). HA-KCTD9 puncta co-localized with 
RFP-LC3 in complete media and under starvation conditions there was an increase in the 
amount of co-localization (Fig. 7B, 7C, 8A). Although not all of the HA-KCTD9 puncta 
localized to the autophagosomes, it is possible that a certain amount of KCTD9 
translocated to autophagosomes, more when autophagy was induced.  
 In order to see if KCTD9 co-localizes with other autophagy markers, different 
markers of the autophagy process were tested. Vps34-FLAG, an early marker of the 
autophagy process, was expressed in COS7 cells and formed a extended network in cells 
grown in complete media, but under starvation conditions puncta were observed (Fig. 
9A). When co-expressed with HA-KCTD9 in complete media, KCTD9 induced the 
formation of puncta positive forVps34 (Fig. 9B). When starved, there was more co-
localization seen between KCTD9 and Vps34 (9C, 10A). These results suggest that 
KCTD9 may be playing role in autophagy induction by virtue of its co-localization with 
the PI3K Vps34.  Furthermore, HA-KCTD9-194x induces the change in structure of 
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Vps34-FLAG, which is normally diffuse but co-expressed causes it to form small puncta 
like HA-KCTD9-194x (Fig. 9D). HA-KCTD9-194x did not cause a morphological 
change with other autophagy proteins including LC3 and Atg5 (data not 
shown).  Interestingly, KCTD9 does not co-localize with the FYVE-domain, a domain 
found in autophagy proteins such as WIPI-1. FYVE-domain containing proteins can bind 
to PI(3)P, therefore acting downstream of the PI3K Vps34 (Kutateladze et al., 2001). 
Expressing FYVE-dsRed in COS7 cells results in the formation of small cytoplasmic 
puncta and under starvation conditions results in the formation of more cytoplasmic 
puncta (Fig. 11A). These cytoplasmic puncta are very reminiscent of the puncta formed 
by KCTD9. However, when co-expressed with KCTD9 in complete media or starvation, 
the puncta do not co-localize, but instead seem to be next to each other (Fig 11B, 11C). 
Furthermore, KCTD9 puncta seem to cluster into larger structure as they are outcompeted 
by FYVE. It is possible that the FYVE-domain and KCTD9 are competing for similar 
regions of PI(3)P and that both are involved in the early formation of autophagosomes. 
 Another autophagy protein that KCTD9 co-localized with was Atg5, which is 
required for the lipidation of LC3 with phosphatidylethanolamine (PE) and recruitment of 
LC3 to autophagosomes (Hanada et al., 2007). When expressed in COS7 cells mCherry-
Atg5 is diffuse, but under starvation conditions starts to form puncta (Fig. 12A). 
Following co-expression of mCherry-Atg5 and KCTD9, HA-KCTD9 induced the 
formation of mCherry-Atg5 puncta that are also positive for KCTD9 in complete media, 
and more co-localization in puncta containing these 2 proteins was visible under 
starvation conditions (Fig. 12B, 12C, 13A). These results suggest that KCTD9, which 
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localized with LC3-marked autophagosomes, can possibly induce autophagosome 
formation and co-localizes with autophagosome proteins Vps34 and Atg5.         
 
KCTD9 localizes to subdomains of the endoplasmic reticulum  
 The ER is considered to be a possible membrane source for the autophagosome. 
Since KCTD9 co-localized with early autophagosomal marker Vps34, it is possible that 
KCTD9 localizes to sites of autophagosomal formation on the ER (Geng et al., 2010).  In 
order to visualize the ER, Climp63-FLAG, a cytoskeleton-linking ER membrane protein, 
was expressed in COS7 cells forming an interconnected network of ER (Fig. 14A) 
(Nikonov et al., 2007). When Climp63-FLAG was co-expressed with HA-KCTD9, the 
“vesicle-like” puncta localized within the interconnected network of Climp63-FLAG 
(Fig. 14B). Furthermore, when Climp63-FLAG was co-expressed with HA-KCTD9ΔN, 
which was thought to be reminiscent of ER, HA-KCTD9ΔN structure followed a similar 
pattern to that of Climp63-FLAG (Fig. 14C).  
 To further investigate whether KCTD9 associates with the ER, a flipped-
Reticulon4b construct was used. Reticulon4b is an ER associated protein that plays a role 
in the ER’s tubular morphology (Voeltz et al., 2005). The flipped-Reticulon4b construct 
causes the collapse of the ER around the nucleus. When the HA-flipped-Reticulon4b 
construct was expressed in COS7 cells, the ER condensed around the nucleus as marked 
by the dotted lines (Fig. 15A). Co-expression of HA-flipped-Reticulon4b and GFP-
KCTD9 not only resulted in GFP-KCTD9 structures localizing within the condensed ER, 
but “vesicle-like” puncta were no longer present (Fig. 15B). By changing the shape of the 
ER, KCTD9 structures were also changed indicating that KCTD9 possibly is associated 
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to certain subdomains of the ER. On the other hand, expression of a dsRed construct 
containing the FYVE domain localize to the outer region of the HA-flipped-Reticulon4b 
(Fig. 15C). The dsRed-FYVE makes puncta that seem to localize at the edge, but the 
puncta of FYVE are not distorted like that of KCTD9. These results suggest that KCTD9 
may localize to different regions of the ER in comparison to FYVE domain-containing 
proteins.    
 
Endogenous expression of KCTD9 in N2a cells  
 While expression of KCTD9 in two different cell lines have provided us some 
insight into the localization of the protein, and possible function of  KCTD9 in the 
autophagy pathway, remains be demonstrated. One autophagy assay involves looking at 
LC3-II levels, as a sign of active autophagy (Klionsky et al., 2012). In order to perform 
the autophagy assay, we used a commercial antibody (Genetex Cat. # 
GTX119656) against KCTD9 that cross-reacts with endogenously expressed KCTD9. 
Three cell lines were tested and N2a cells had a high level of endogenous KCTD9 
expression (Fig. 16A). In addition, a five-week old NIH Swiss mouse was dissected to 
obtain tissue lysates (Fig. 16A), showing endogenous expression of KCTD9 in the 
cerebellum, liver, and spleen lysates.  
In order to confirm endogenous expression of KCTD9 in N2a cells, an 
immunofluorescence experiment was performed using the commercial antibody. 
Endogenous KCTD9 puncta look similar to overexpressed KCTD9 in N2a cells (Fig. 16B 
left). However, certain puncta had a nuclear localization (Fig. 16B right). Cheng et al. 
reported that KCTD9 was mainly localized in the cytoplasm of PBMCs, but could be 
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translocated to the nucleus in HBV-ACLF patients (2013). Therefore, it is possible that 
KCTD9 has the ability to translocated into the nucleus as illustrated by endogenous 
staining, but overexpression may end up preventing the translocation as only cytoplasmic 
puncta were visible.   
 
KCTD9 knockdown leads to autophagy defect  
When autophagy proteins are knocked down, there is a change in LC3 levels - 
detectable by western blot. When KCTD9 levels were decreased in N2a cells there was a 
concommittant decrease in LC3-II levels, in comparison to the untransfected control and 
scramble siRNA. In the untransfected control and scramble siRNA cells, bands for LC3-I 
and LC3-II  were apparent suggestive of basal level of autophagy occurring in the cells. 
However, when KCTD9 is partially knocked down, there is a decrease in the amount of 
LC3-II (Fig. 17). While these are preliminary results, it is possible that there is a decrease 
in the conversion of LC3-I to LC3-II due to a block in the pathway. KCTD9 may be 
playing a role in the early induction stages of the pathway, and in the absence of this 
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Discussion  
 This research is the first to specifically focus on KCTD9’s morphology, 
subcellular localization, and function. KCTD9 forms distinct cytoplasmic puncta in 
COS7 and N2a cells, which fall within the range of autophagosomes. Furthermore, 
KCTD9 puncta range in size from small round to puncta to more vesicle-like structures 
that may possibly be carrying cargo. As a Cullin-3 substrate adaptor, KCTD9 has the 
ability to bind certain substrates and target them for degradation. While Cullin-3 
ubiquitinated proteins usually are degraded by through proteasomal machinery, it is 
possible that Cullin-3 plays a role in trafficking pathways (Huotari et al., 2012). With its 
newly discovered role in endosomal trafficking, Cullin-3 along with KCTD9 may be 
involved in the autophagy pathway by either targeting certain proteins for degradation or 
acting as chaperones for autophagy-related proteins. In the future, co-
immunoprecipitation experiments can be performed in order to confirm the interaction 
between Cullin-3 and KCTD9. Then determining if Cullin-3 co-localizes with autophagy 
markers and if deletion of Cullin-3 results in autophagy defects.    
In order to determine KCTD9’s subcellular localization, it was co-expressed with 
numerous cellular markers. While KCTD9 did not localize with endosomal markers, it 
localized with autophagy markers. In numerous cells, KCTD9 and LC3, an 
autophagosome-marker, co-localized and stimulation of autophagy resulted in an increase 
of co-localization. Furthermore, KCTD9 co-localized even more strongly with other 
autophagy proteins like Vps34 and Atg5. These results indicate that KCTD9 may be an 
autophagosome-associated protein playing a potential role in the early stages of the 
autophagy pathways. 
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Some autophagosomes are known to be derived from the ER and KCTD9 
associated with ER marker like Climp63 and remains associated with the ER upon shape 
change of the ER induced by Flipped-Reticulon 4b. These results suggest that KCTD9 
may localize to certain subdomains of the ER where autophagosomes derive from (Fig. 
18). In order to confirm these results it will be interesting to determine how KCTD9 
associates with the ER and its specific role in the derivation of autophagosomes. Our 
hypothesis is that KCTD9 interacts to certain subdomains of the ER through its C-
terminus because of the similar ER morphology. An autophagy assay was used in order 
to determine if KCTD9 plays a functional in the autophagy pathway, as suggested by its 
localization to autophagosomes. Partial knockdown of KCTD9 results in a reduction in 
LC3-II levels suggesting for a functional role of KCTD9 in the early induction of the 
autophagy pathway. Due to the co-localization with nucleation and elongations 
autophagy markers with KCTD9 and its effect in the autophagy assay we believe that 
KCTD9 may play a potential in the induction of the autophagy pathway. While more 
research needs to be done in order to confirm the role of KCTD9 in the autophagy 
pathway these results suggest that KCTD9 may be a novel autophagosome-associated 
protein.  
This research will pave the way for further studies on theKCTD9’s role in 
autophagy and its link it to immunology and virology. KCTD9 has been implicated in 
NK cell activation, but the exact mechanism is unknown (Chen et al., 2013). It is possible 
that NK cell activation occurs through autophagy involving KCTD9. Autophagy-
associated proteins such as Atg5 have been found to be involved in B and T cell 
activation (Kuballa et al., 2012). However, more research needs to be done in order to 
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understand the role of autophagy in NK cell activation and proliferation. Furthermore, 
KCTD9 expression increases in patients with chronic HBV infections, and HBV is 
known to induce autophagy for viral replication to occur (Chen et al., 2013; Li et al., 
2011). If KCTD9 is involved in the induction of autophagy, then it may be targeted by 
HBV to stimulate viral replication. A lot more attention needs to be dedicated to specify 
the exact function of KCTD9 because it could act a therapeutic target for autophagy-




















          
        
    
    
  
   
 
Figure 1. KCTD9 constructs design. (A) KCTD9 full-length protein of 389 amino acids 
with domains - KHA, BTB, and pentapeptide repeats. (B) Tagged versions of KCTD9 













































Figure 2. Expression of KCTD9 in COS7 cells leads to formation of cytoplasmic 
puncta. (A) Immunofluorescence microscopy of COS7 cells transfected with HA-
KCTD9 (anti-HA, red) for 19 h; nuclei stained with DAPI (blue). (B) Quantification of 
various HA-KCTD9 puncta found in COS7 cells 19 h post-transfection (n=3). (C) 
Immunofluorescence microscopy of COS7 cells transfected with GFP-KCTD9 (anti-
GFP, green) or E-GFP (anti-GFP, green) for 19 h; nuclei stained with DAPI (blue).  
 
 






Figure 3. KCTD9 forms similar cytoplasmic structures in N2a cells.  
(A) Immunofluorescence microscopy of N2a cells transfected with HA-KCTD9 (anti-
HA, red) for 19 h; nuclei stained with DAPI (blue). (B) Quantification of various HA-
KCTD9 puncta found in N2a cells 19 h or 40 h post-transfection (n=3). (C) Western blot 
showing level of KCTD9 (anti-HA) at 19 or 40 h post-transfection; Hsp90 detected with 












Figure 4. KCTD9 can self-interact via BTB mutant. (A) KCTD9 mutants in COS7 cells 
detected with anti-HA antibody (red); nuclei stained with DAPI (blue). (B) KCTD9 mutants 
in N2a cells detected with anti-HA antibody; nuclei stained with DAPI (C) Co-
immunoprecipitation of GFP-KCTD9 and BTB-containing mutant HA-KCTD9-194x.    
 
 
Figure 5. KCTD9 co-localizes with Cullin-3. (A) Immunofluorescence microscopy of 
COS7 cells transfected with Cullin-3-myc (anti-myc, green); nuclei stained with DAPI 
(blue). (B) Co-expression of HA-KCTD9 (anti-HA, red) and Cullin-3-myc (anti-myc, 
green) 19h post-transfection; nuclei stained with DAPI (blue) (C) Co-expression of 
KCTD9 mutant (anti-HA, red) and Cullin3-myc (anti-myc, green) post 19 h; nuclei 













Table 1. Summary of co-localization results between endosomal markers and 
KCTD9. Numerous immunofluorescence experiments were performed in order to 
determine if endosomal markers and KCTD9 co-localize as outlined above. These 
experiments were performed in COS7 and N2a cells with no treatment or treatment - 
































Figure 6. KCTD9 does not co-localize with endosomal markers. (A) HA-KCTD9 
(anti-HA, green) co-expressed with RFP-Rab5 (direct fluorescence, red); nuclei stained 
with DAPI (blue). (B) HA-KCTD9-194x (anti-HA, green) co-expressed with RFP-Rab5 
(direct fluorescence, red); nuclei stained with DAPI (blue). (C) HA-KCTD9 (anti-HA, 
red) co-expressed with GFP-Rab7 (anti-GFP, green); nuclei stained with DAPI (blue). 
(D) HA-KCTD9 (anti-HA, green) co-expressed with RFP-Lamp1 (direct fluorescence, 
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Table 2. Summary of co-localization results between autophagy markers and 
KCTD9. Numerous immunofluorescence experiments were performed in order to 
determine autophagy markers that KCTD9 co-localizes with as outlined above. These 








Figure 7. KCTD9 co-localizes with autophagosome marker LC3. (A) 
Immunofluorescence microscopy of COS7 cells transfected with tagRFP-LC3 (direct 
fluorescence, red) in complete or amino acid and serum free media for 5 h; nuclei stained 
with DAPI (blue). (B) Co-expression of HA-KCTD9 (anti-HA, green) and tagRFP-LC3 
(direct fluorescence, red) 19h post-transfection; nuclei stained with DAPI (blue) (C) Co-
expression of HA-KCTD9 (anti-HA, green) and tagRFP-LC3 (direct fluorescence, red) 































Figure 8. Starvation induces LC3 puncta and  increases co-localization with 
KCTD9. (A) Quantification of COS7 cells transfected with tagRFP-LC3 comparing 
diffuse and puncta in complete and starvation media. (B) Number of LC3 puncta 
averaged in 25 cells per experiment (n=3). (C) Quantification of co-localization between 






Figure 9. KCTD9 co-localizes with early autophagosome marker Vps34. (A) 
Immunofluorescence microscopy of COS7 cells transfected with Vps34-FLAG (anti-
FLAG, green) in complete or amino acid and serum free media for 5 h; nuclei stained 
with DAPI (blue). (B) Co-expression of HA-KCTD9 (anti-HA, red) and Vps34-FLAG 
(anti-FLAG, green) 19h post-transfection; nuclei stained with DAPI (blue) (C) Co-
expression of HA-KCTD9 (anti-HA, red) and Vps34-FLAG (anti-FLAG, green) 19h 


























Figure 10. KCTD9 induces Vps34 puncta in complete and starvation media. (A) 
Quantification of immunofluorescence microscopy of COS7 cells co-transfected with 
Vps34-FLAG and HA-KCTD9 in complete media or media to stimulate autophagy. CM: 
complete media. SM: media with 50 nM rapamycin for 2 hours or amino acid and serum 








Figure 11. KCTD9 does not co-localize with FYVE-domain. (A) Immunofluorescence 
microscopy of COS7 cells transfected with FYVE-dsRed (direct fluorescence, red) in 
complete or amino acid and serum free media for 5 h; nuclei stained with DAPI (blue). 
(B) Co-expression of HA-KCTD9 (anti-HA, green) and FYVE-dsRed (direct 
fluorescence, red) 19h post-transfection; nuclei stained with DAPI (blue) (C) Co-
expression of HA-KCTD9 (anti-HA, green) and FYVE-dsRed (direct fluorescence, red) 
19h post-transfection after 5 h starvation; nuclei stained with DAPI (blue).  








Figure 12. KCTD9 co-localizes with autophagy protein Atg5. (A) 
Immunofluorescence microscopy of COS7 cells transfected with mCherry-ATG5 (direct 
fluorescence, red) in complete or amino acid and serum free media for 5 h; nuclei stained 
with DAPI (blue). (B) Co-expression of HA-KCTD9 (anti-HA, green) and mCherry-
ATG5 (direct fluorescence, red) 19h post-transfection; nuclei stained with DAPI (blue) 
(C) Co-expression of HA-KCTD9 (anti-HA, green) and mCherry-ATG5 (direct 










Figure 13. KCTD9 induces Atg5 puncta in complete and starvation media. (A) 
Quantification of immunofluorescence microscopy of COS7 cells co-transfected with 
mCherry-Atg5 and HA-KCTD9 in complete media or media to stimulate autophagy. CM: 
complete media. SM: media with 50 nM rapamycin for 2 hours or amino acid and serum 




Figure 14. KCTD9 full-length and mutant construct associate with endoplasmic 
reticulum marker Climp63. (A) Immunofluorescence microscopy of COS7 cells 
transfected with Climp63-FLAG (anti-FLAG, green); nuclei stained with DAPI (blue). 
(B) Co-expression of HA-KCTD9 (anti-HA, red) and Climp63-FLAG (anti-FLAG, 
green) post 19 h; nuclei stained with DAPI (blue) (C) Co-expression of HA-KCTD9ΔN 









Figure 15. KCTD9 localizes to subdomains of the endoplasmic reticulum in COS7 
cells. (A) Immunofluorescence microscopy of COS7 cells transfected with Flipped-
Reticulon4b (anti-HA, red); detected by DAPI (blue), confocal phase image presented. 
(B) GFP-KCTD9 (anti-GFP, green) co-expressed with HA-Flipped-Reticulon4b (anti-
HA, red); nuclei detected by DAPI (blue), confocal phase image presented. (C) FYVE-
dsRED (direct fluorescence, red) co-expressed with HA-Flipped-Reticulon4b (anti-HA, 













Figure 16. Endogenous expression of KCTD9 in N2a cells. (A) Use of GeneTex anti-
KCTD9 antibody for endogenous detection - high level of expression in N2a cells. (B) 
Endogenous detection of KCTD9 in N2a cells - puncta in nucleus. (C) Endogenous 







Figure 17. KCTD9 siRNA knockdown leads to possible autophagy induction defect. 
(A) Dharmacon siRNA smartpool for KCTD9  was used in order to knockdown KCTD9 
in N2a cells. While there was not total knockdown, there was a change in LC3-I and 
LC3-II levels when KCTD9 was partially knocked down indicating a possible defect 





















Figure 18. Model of KCTD9’s potential role in the autophagy pathway. (A) KCTD9 
localizes to certain subdomains of the ER where the autophagosomes develops from. 
KCTD9 may be playing a role in inducing pre-autophagosomal sites and promoting the 
development of autophagosomes. Therefore co-localization is seen with Vps34, Atg5, 
and LC3. Furthermore, knocking down KCTD9 leads to a defect in formation of 
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